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Abstract
During the last two decades, mutations in sarcomere genes have found to comprise the
most common cause for hypertrophic cardiomyopathy (HCM), but still significant number of
patients with dominant HCM in the family are left without molecular genetic diagnosis. Next
generation sequencing (NGS) does not only enable evaluation of established HCM genes
but also candidate genes for cardiomyopathy are frequently tested which may lead to a situ-
ation where conclusive interpretation of the variant requires extensive family studies. We
aimed to characterize the phenotype related to a variant in the junctophilin-2 (JPH2) gene,
which is less known non-sarcomeric candidate gene. In addition, we did extensive review of
the literature and databases about JPH2 variation in association with cardiac disease. We
characterize nine Finnish index patients with HCM and heterozygous for JPH2 c.482C>A, p.
(Thr161Lys) variant were included and segregation studies were performed. We identified
20 individuals affected with HCM with or without systolic heart failure and conduction abnor-
malities in the nine Finnish families with JPH2 p.(Thr161Lys) variant. We found 26 heterozy-
gotes with the variant and penetrance was 71% by age 60 and 100% by age 80. Co-
segregation of the variant with HCM phenotype was observed in six families. Main clinical
features were left ventricular hypertrophy, arrhythmia vulnerability and conduction abnor-
malities including third degree AV-block. In some patients end-stage severe left ventricular
heart failure with normal or mildly enlarged diastolic dimensions was detected. In conclu-
sion, we propose that the heterozygous JPH2 p.(Thr161Lys) variant is a new Finnish muta-
tion causing atypical HCM.
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Introduction
Hypertrophic cardiomyopathy (HCM) is considered the most common form of inherited car-
diomyopathies estimated to affect one in 500 in general population [1]. Diagnosis of HCM is
made by two-dimensional echocardiography showing hypertrophied, non-dilated left ventricle
(LV) in the absence of other cardiac or systemic causes of hypertrophy such as aortic valve ste-
nosis or hypertension [2]. HCM may manifest at any age but typically in the adulthood. The
clinical course of the disease varies significantly from person to person. Some patients remain
asymptomatic through their life whereas others suffer from arrhythmias or embolic stroke,
develop severe heart failure or experience sudden cardiac death (SCD) even at early age [3–5].
Hereditary HCM is a dominant disorder, commonly associated with mutations in sarco-
mere genes. Phenocopies of HCM include Anderson-Fabry disease (galactosidase alpha, GLA),
Danon disease (lysosomal-associated membrane protein 2, LAMP2), PRKAG2 related glycogen
storage disease (protein kinase AMP-activated non-catalytic subunit gamma 2, PRKAG2), car-
diac amyloidosis, neuromuscular diseases and malformation syndromes (Noonan spectrum
syndromes).[6] Genetic diagnostics has proven as an effective strategy to differentiate between
potential underlying causes and to rule out phenocopies. Accurate molecular genetic diagnosis
helps to detect the genetic cause of those phenocopies that might require special therapy (e.g.
enzyme replacement therapy) [7–9].
The most established genes associating with HCM are myosin binding protein C
(MYBPC3), myosin heavy chain 7 (MYH7), troponin I3, cardiac type (TNNI3), troponin T2,
cardiac type (TNNT2), tropomyosin 1 (TPM1), myosin light chain 2 (MYL2), myosin light
chain 3 (MYL3) and actin, alpha, cardiac muscle 1 (ACTC1) [10]. The role of candidate genes
such as troponin C1, slow skeletal and cardiac type (TNNC1) [11] and actinin alpha 2
(ACTN2) [12] has remained obscure. Diagnostic yield of molecular genetic testing in daily
practice is 25–40% in HCM [10]. This demonstrates the challenge of differentiating genetic
disease from acquired conditions or other systemic diseases and indicates that there are novel
disease genes and more complex genetic variations left to be discovered. Although it has been
difficult to demonstrate phenotypic correlations between different genes and different muta-
tions, there is a significantly worse outcome in patients tested positive vs. negative for muta-
tions in sarcomere genes [13]. A large proportion of the mutations are unique for a family and
have not been reported before. In certain populations, however, founder mutations comprise a
large part of detected mutations. To date HCM founder mutations have been identified in
MYBPC3, MYH7 and TPM1 genes, and reported in the Netherlands [14], Spain [15], South
Africa [16], Finland [17], Italy [18], Japan [19], South Asia [20] and in the Amish population
[21].
Junctophilin-2 gene (JPH2) is the major structural protein in cardiomyocytes for coupling
of transverse (T) tubule-associated L-type Ca2+ channels and type-2 ryanodine receptors on
the sarcoplasmic reticulum within junctional membrane complexes (JMC) [22, 23]. Signaling
between these two Ca2+ channels is required for normal cardiac contractility. Disruption of
the JMC is a common finding in failing hearts. Downregulation of JPH2 gene has been associ-
ated with heart failure and mutations in this gene have been suggested to associate with HCM.
JPH2 was initially published as candidate gene for HCM in 2007 when Matsushita et al. found
p.(Gly505Ser) in four probands among 148 Japanese HCM patients [24] but this variant was
later found to be a common polymorphism present in up 4–6% in Asian/African populations.
Role of the JPH2 in cardiomyopathies has been obscure as only one rare variant segregating
with any type of cardiomyopathy has been published [25].
In this study, we characterize the cardiac phenotype related to JPH2 c.482C>A, p.
(Thr161Lys) variant in nine Finnish index patients and their family members. We also review
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evidence gathered from the literature and variant databases that supports or is against the
pathogenicity of the mutations in JPH2 to highlight challenges we have when rare gene vari-
ants from candidate genes are detected.
Subjects and methods
The methods for this trial is available as supporting information; see S1 Protocol http://dx.doi.
org/10.17504/protocols.io.[PROTOCOL]
Index patients with the JPH2 variant c.482C>A, p.(Thr161Lys) and their relatives from
four Finnish hospitals were included. A written informed consent was obtained from all par-
ticipants. This study has been approved by the Ethical Review Committee of the Department
of Medicine, University of Helsinki (Dnro 307/13/03/01/11) and by the Ethical Review Com-
mittee of the Department of Medicine, University of Tampere (R08070) and conforms to the
ethical principles outlined in the Declaration of Helsinki.
HCM was clinically diagnosed according to ESC Guidelines [2]. Hypertrophic cardiomyop-
athy (HCM) is defined by the presence of increased LV wall thickness that is not solely
explained by abnormal loading conditions. In adults, the diagnosis of HCM requires LV wall
thickness15 mm as measured by any imaging technique. Correspondingly, the clinical diag-
nosis of HCM in first-degree relatives of patients with LVH15 mm is based on the presence
of otherwise unexplained increased LV wall thickness13 mm. In children, the diagnosis of
HCM requires LV wall thickness more than two standard deviations greater than the predicted
mean.
Family history was obtained and pedigrees were drawn. The adult participants were
assessed clinically at Heart and Lung Center, Helsinki University Hospital, at the Heart Hospi-
tal, Tampere University Hospital or at the Seina¨joki Central Hospital by physical examination,
resting 12-lead ECG, appropriate laboratory tests and transthoracic echocardiography (TTE).
Cardiac MRI was performed in some cases especially in patients with borderline diagnostic
findings at echocardiography. All participants are of Finnish ethnicity.
Molecular genetic studies
Genetic testing was carried out from genomic DNA using the OS-Seq™ (oligonucleotide-selec-
tive sequencing) next-generation sequencing method [26, 27]. The genetic evaluation of the
index patients was performed using the Blueprint Genetics Core Cardiomyopathy or Pan Car-
diomyopathy Panels covering 69 and 103 genes, respectively, associated with cardiomyopa-
thies and their genetic phenocopies (Supplementary file 1). The presence of the variant in
probands’ relatives was studied by bi-directional Sanger sequencing.
Results
Genetic studies
A heterozygous JPH2 c.482C>A, p.(Thr161Lys) (NM_020433.4) variant was observed in nine
unrelated Finnish probands with cardiomyopathy. Altogether the p.(Thr161Lys) was detected
in 20 affected individuals. The variant co-segregated with HCM in six families (Families 2–4,
6–8, Fig 1) and in three families the mutation was found only in the probands (Family 9), in
probands and young family member without HCM (Family 1) or in probands and in another
family member without HCM (Family 5). Systolic heart failure or conduction abnormalities
were observed in every family. These features were present in 12/20 (60%) of the affected
patients including ten heterozygous affected individuals and two obligate carriers. The p.
(Thr161Lys) was absent in three family members without LV hypertrophy who were over 20
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years of age (3.I.2, 5.I.2, 8.II.2). It was also absent in asymptomatic 60-year old female (Family
6.I.2) who was not evaluated clinically and two individuals with LVH likely explained by severe
hypertension (Family 4:I.3 and Family 8:I.2). Pedigrees of the families 2–8 are presented in Fig
1. This heterozygous missense variant has not been observed in the Exome Aggregation Con-
sortium (ExAC) data set, comprised in total of over 60,000 unrelated individuals or in the
Genome Aggregation Database (gnomAD; total of 126,216 exomes and 15,137 genomes). In
silico bioinformatic tools Polyphen, SIFT and Mutation Taster predict it to be deleterious.
Threonine is conserved amino acid at this position among mammals.
The main clinical characteristics of the probands and family members are shown in
Table 1. These include left ventricular hypertrophy (LVH), and in some cases end-stage severe
left ventricular (LV) failure with normal or mildly dilated LV. Average at diagnosis was 26.9
±20.6 years in the nine probands and their maximum LV wall thickness was 20.4±5.2 mm at
age of 34.1. Atrial or ventricular arrhythmias considered abnormal were observed in 13/20
(65%) of the heterozygotes. Pacemaker (PM) or ICD was implanted in 6/20 (30%) and reduced
Fig 1. Pedigrees of seven families affected with the JPH2 c.482C>A, p.(Thr161Lys), (rs587782951, NM_020433.4) variant. Pedigrees of three families affected with
the JPH2 c.482C>A, p.(Thr161Lys), (rs587782951, NM_020433.4) variant. Circles represent women, squares men and triangles gender blinded. Black-filled symbols
represent individuals who fulfill ESC 2008 diagnostic criteria for HCM with [2]. We also considered as affected with HCM one family member (Family 8:I.3) who had
imminent cardiomyopathy with borderline LVH (12 mm), 3-degree AV block, RBBB and severe systolic heart failure. Genotypes: +/- heterozygous for the JPH2 p.
(Thr161Lys), -/- wild type allele,  MYBPC3 p.(Gln1061). Age of the family members at last follow-up, maximum LV wall thickness and some other key signs of clinical
disease are listed below the symbols. Arrows indicate index patients. Abbreviations listed in Table 1.
https://doi.org/10.1371/journal.pone.0203422.g001
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Table 1. Clinical characteristics of the probands and their family members.
Family Age
(M/
F)
Genotype Conduction
defect
Arrhythmias PM,
ICD
LV-
WT
LVEDD
(mm)/ EF (%)
proBNP
(ng/l)
Age at
dg
Phenotype Other
Family 1
I.1 52M +/- no AF ICD 20 46/56% 400 47 HCM
Family 2
I.1 44M +/- no no no 16 46/72% 76 44 HCM
II.1 12M +/- no VT no 23 48/77% 315 12 HCM
II.2 16M +/- pRBBB no no 6 51/63% NA - normal
Family 3
I.1 48M +/- RBBB no no 15 49/72% 44 41 HCM
II.1 24M +/- LBBB VT ICD 29 44/75% 145 13 HOCM Pk-grad 81mmHg
Family 4
I.2 45M n.a. AVB3, LAHB,
RBBB
AF, VT PM 28 55/20% 8425 17 HOCM,
SHF
Pk-grad 50mmHg
Died 45 y
I.3 57F -/- no no no 14 43/60% 33 - LVH/
Hypertens
BP 160/110 mmHg
II.1 25M +/- no SVT no 22 45/67% 104 9 HCM
II.2 17M +/- LAHB no no 20 49/55% NA 1 HCM
III.3 8M +/- no no no 11 35/>50% NA 1 HCM
Family 5
I.1 54M +/- no SVT no 10 50/70% NA - normal SVT ablation
I.2 53F -/- no no no 11 44/83% 164 - normal
II.1 25F +/- RBBB, LAHB VES, VT,
SVT
no 22 43/60% 5700 12 HCM, SHF Multiple VSDs, PDA operated aged 2
years. During pregnancy LVEF 45%
Family 6
I.1 62M +/-, LAHB AF no 15 40/52% 998 61 HCM
I.2 60F -/- NA NA NA NA NA NA - NA
II.1 F (+/-,) NA NA NA NA NA NA - HCM
III.1 8F +/-, NA no no 11 33/>60% 3928 7 HCM
Family 7
I.2 76F +/- LAHB AF no 27 49/56% NA ? HCM
I.3 72F +/- no AF no 17 45/60% NA ? HCM
I.4 80F (+/-) no AF no NA NA NA ? ? Died age 80 y
II.1 52M +/- AVB1 VES, SVT no 23 49/63% NA 43 HCM
II.2 49M +/- AVB1 no no 21 60/50% NA ? HCM
II.3 48M +/- no no no 11 NA NA - normal
III.1 20F +/- no SVT no 12 44/66% NA 19 normal
Family 8
I.1 43F (+/-) AVB3, LBBB AF, VT PM 18 70/30% 6637 25 HCM, SHF Died aged 43. HF. WT at autopsy 15
mm.
I.2 60F -/- no no no 13 40/71% 160 - LVH/
Hypertens
I.3 76F +/- AVB3, LAHB,
RBBB
no PM 12 46/40% 5267 67 HCM Mixed cardiomyopathy
II.1 47M +/- AVB1, LBBB AF, VT ICD 15 51/37% 4426 36 HCM, SHF
II.2 49F -/- no no no 10 49/66% 31 - normal
III.1 15M +/- no no no 7 46/66% NA - normal
Family 9
(Continued)
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LVEF (<47%) or elevated proBNP concentration (>300 ng/l) was observed in 9/20 (45%) of
the patients. Penetrance of HCM was 48%, 71% and 100% by age of 40, 60 and 80, respectively.
Family 1. Proband of this family was diagnosed HCM at age 47. His genotype positive
(not drawn on pedigree) son was phenotype negative with maximal wall thickness of 10 mm at
age 22, which is in line with age-dependent penetrance of cardiomyopathies.
Family 2. Proband (II.1) of family 2 developed HCM at age of 12 and has significant bur-
den of arrhythmias. Subsequently, his genotype positive father was found to have also HCM
and arrhythmias. Proband’s brother was genotype positive yet phenotype negative at age of 16.
Family 3. Proband (II.1) developed HCM at age of 13 and LV wall thickness increased up
to 29 mm by age 24. He had also LVOT obstruction with 81mmHg systolic gradient. The
patient was prescribed beta blockers and disopyramide, and LVOT gradient decreased to
20mmHg. His symptoms, chest pain and shortness of breath presenting during light walking,
were suppressed by the medication. His genotype positive father has also HCM but no arrhyth-
mias. The proband has ventricular arrhythmias. Both affected individuals in this family have
preserved systolic function.
Family 4. Proband (II.1) is a male with clinical diagnosis of HCM at age 9. He has had
recurrent episodes of sustained atrial tachyarrhythmias. On echocardiography, maximal LV
wall thickness was 22mm. Proband’s 17-year-old genotype positive brother (II.2.) had maximal
LV thickness of 20mm. He and proband’s son were diagnosed at very early age. Proband’s
father (I.2) was diagnosed with HCM aged 17 years as his ECG showed inferolateral T-inver-
sions like the ECGs of his both sons and echocardiography revealed septal thickness of 17mm.
Later he developed variable 2–3 degree AV block and received pacemaker. He had also LVOT
obstruction with 50mmHg systolic gradient. The patient was prescribed beta blockers and dis-
opyramide and LVOT gradient decreased to 21 mmHg. At age 26, his LVEF was 70%. During
the follow-up, maximal septal thickness increased to 28mm and posterior wall to 20mm. The
patient had paroxysmal atrial flutter and later chronic atrial fibrillation (AF). By the age of 40
years, the patient developed NYHA 3 dyspnea and his LVEDD was 58mm, LVEF 40% and sep-
tal thickness 18mm. He had right heart failure and ascites, proBNP was 8425ng/l. Aged 45
years LVEDD was 55mm and LVEF 20–25%. The patient was listed for heart transplantation
but died aged 45 years due to heart failure and sepsis. He deceased before the NGS technology
became to clinical use and his genotype remains unknown. His disease fits well with the phe-
notype described here in genotype positive individuals. Genotype of proband’s mother is also
unknown, thus we were not able to confirm that the JPH2 variant was inherited from the
affected parent. Index patient’s father’s mother had also HCM and died aged 42 years while
Table 1. (Continued)
Family Age
(M/
F)
Genotype Conduction
defect
Arrhythmias PM,
ICD
LV-
WT
LVEDD
(mm)/ EF (%)
proBNP
(ng/l)
Age at
dg
Phenotype Other
I.1 63F +/- no AF PM 19 45/60% 4082 63 HCM
Index patients are marked in bold. Symbols and abbreviations: Age (M/F)–age and gender (M, male; F, female); Genotype–+/- is heterozygous and (+/-) obligatory
heterozygous for p.(Thr161Lys) in JPH2 and -/- is wild type,  heterozygous for MYBPC3 Gln1061; R/LBBB–presence of right/left bundle branch block; LAHB–left
anterior hemiblock; AVB1-3 –atrioventricular block types 1–3; Arrhythmias–AF for atrial fibrillation/flutter, SVT for supraventricular tachycardia (>10 episodes short
episodes per day or SVT requiring cardioversion), VT for ventricular tachycardia 3 beats with frequency>100/min, VES for ventricular extrasystoles>1000 per day,
SVES for supraventricular extrasystoles >5000 per day; PM, ICD, CRT-P/D–pacemaker, implantable cardioverter-defibrillator, cardiac resynchronization therapy
device; LV-WT-maximal left ventricular wall thickness measured by echocardiography or cardiac MRI; LVEDD & EF–left ventricular end-diastolic diameter (mm) and
ejection fraction (%); Age at dg-age at diagnosis of cardiomyopathy; Phenotype–phenotype at diagnosis, HCM–hypertrophic cardiomyopathy, LVH–left ventricular
hypertrophy; SHF–systolic hear failure; Other–other significant clinical features
https://doi.org/10.1371/journal.pone.0203422.t001
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sleeping and her father (proband’s father’s maternal grandfather) died aged 45 years due to an
assumed cardiogenic reason (not drawn in pedigree). As a whole probands and two adult fam-
ily members heterozygous for the variant fulfilled the criteria for HCM, whereas one individual
(I.3), who is negative for the variant has LVH likely explained by severe hypertension (blood
pressure 160/110mmHg) and obesity (BMI 32 kg/m2).
Family 5. Proband (II.1) had multiple VSDs, mild mitral stenosis and patent ductus arte-
riosus necessitating surgery aged 2 years. HCM was diagnosed when she was 12. ECG showed
RBBB likely due to previous cardiac surgery, abnormal amount of ventricular and atrial pre-
mature complexes and she also suffers from SVTs and VTs. She had high levels of pro-BNP
(5700 ng/L) although having normal systolic function at echocardiography. Her genotype pos-
itive father has no morphological HCM phenotype but he underwent ablation for SVT with
good response.
Family 6. Proband (III.1) is a girl who developed HCM by the age of 7 years. She has also
a well-established pathogenic nonsense mutation in MYBPC3 (c.3181C>T, p.(Gln1061)). Her
pro-BNP levels are high (3928 ng/L). She has inherited both of the variants from his mildly
affected grandfather through her mother who has HCM and is obligate carrier of both
variants.
Family 7. In this family, the index patient (II.1), his brother (II.2), mother (I.2) and moth-
er’s sister (I.3) were heterozygous for the JPH2 p.(Thr161Lys) variant. They all fulfilled the
imaging criteria of HCM with maximal LV wall thicknesses of 17-27mm. None of these
patients had heart failure. Mother’s other sister (I.4) who was an obligatory carrier died at age
80 due to mesenterial thrombosis. Her son is heterozygous for the JPH2 variant. Twenty-year-
old daughter (III.1) of the index has borderline phenotype (septal thickness 12 mm) and her
ECG showed abnormal Q-waves at I, II, aVF, V5-6 leads and episodes of ectopic atrial rhythm.
Family 8. The index patient (II.1) is heterozygous for the JPH2 p.(Thr161Lys) variant. He
was a previously sportive male who presented with decreased exercise tolerance at the age of
36 years. ECG showed LVH and on echocardiography LV was 51/36mm, EF 55% and septum
14mm at maximum. Five years later septum measured 15mm fulfilling the HCM criteria. At
age of 45, ECG showed sinus rhythm and trifascicular block (LBBB + type 1 AV block). TnT
concentration was constantly increased up to 48 ng/l (normal range< 15ng/l) and proBNP
concentration has increased up to 4426 ng/l. He has had paroxysmal atrial fibrillation (AF)/
flutter and monomorphic ventricular tachycardia (VT). Coronary angiography was normal.
Cardiac MRI demonstrated extensive late gadolinium enhancement (LGE) especially at septal
and anterior regions. FDG-PET did not detect signs of inflammation. Endomyocardial biop-
sies from left and right ventricles remained non-diagnostic and showed mainly fibrosis.
Electrophysiologic study demonstrated VT. On echocardiography, LV was 51mm, septum
14mm, PW 12mm and EF 37%. Hemodynamics were restrictive. The patient has received an
ICD. His mother (I.1) was an obligatory carrier of the variant. She presented with loss of
weight, fainting and palpitations aged 28 years and ECG showed LBBB. In cardiac catheteriza-
tion, LVEDP was elevated and left ventricular cineangiography (LV-cine) showed stiff septum,
compatible with HCM. Eight years later she was examined due to tachycardias and collapse
episodes. Maximum LV wall thickness was 18 mm. In LV-cine, EF was 32%, stroke volume
38ml. The patient received pacemaker due to episodes of syncope and tachyarrhythmia. At age
40 she had atrial fibrillation and 3-degree AV block and at age 42 her LVEDD was 70 mm and
EF 30%. She was treated with digoxin, furosemide, amiodarone, atenolol, captopril and warfa-
rin. Cardiac CT showed dilated left atrium and ventricle but normal pericardium. Before
death at the age of 43, she had heart failure (HF) and repeated VT’s. Autopsy showed fibrotic
changes especially at endocardium of posterior and septal walls. There was very thin and
fibrotic area with a size of 3x4 cm in the anterior LV wall. Maximum wall thickness in autopsy
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was 15mm. Clinical diagnoses comprised cardiomyopathy, endocardial and myocardial fibro-
sis. No material for genotype analysis was available. Mother’s sister (I.3) is also heterozygous
for the p.(Thr161Lys) variant and was considered affected as she has imminent cardiomyopa-
thy with borderline LVH (12 mm), AF, 3-degree AV block, RBBB and severe systolic heart fail-
ure not explained by other causes. She has received a PM. Proband’s non-carrier aunt (I.2) had
mild LVH likely due to hypertension. Proband’s non-carrier brother (II.2) had normal find-
ings in cardiac evaluations as well as proband’s genotype positive son (III-1) who was 15 years
old at last follow-up.
Discussion
We have identified the JPH2 p.(Thr161Lys) variant in nine Finnish index patients with HCM
and have shown co-segregation of the variant with cardiomyopathy in six of these families. In
the other three, only the index person presented HCM phenotype due to the size of the family
or the young age of the variant carriers. This is the first JPH2 variant shown to be causative for
HCM.
For almost twenty years data has accumulated on the role JPH2 in cardiac physiology. How-
ever, little is known about the significance JPH2 as a causative gene for cardiomyopathy. JPH2
is a cardiac specific member of the junctophilins and it has emerged as a potentially important
regulator of excitation-contraction coupling in cardiomyocytes. Several studies have
highlighted the importance of JPH2 for normal cardiac physiology [23, 28]. Mice with acute
conditional cardiac specific knockdown of JPH2 have a high incidence of mortality with a
rapid development of systolic heart failure [29]. These mice demonstrated grossly enlarged
hearts with dilated ventricles and reduced systolic function on echocardiogram. In another
mouse model study, heterozygous JPH2 p.(Glu169Lys) mice had a higher incidence of pacing-
induced AF secondary to abnormal spontaneous Ca[2+] waves and increased spark frequency
[30].
Cardiac phenotype related to this variant differs somewhat from typical HCM. Two Finnish
founder mutations for HCM have previously been published one in myosin binding protein C
(MBPC3) gene and the other in alpha tropomyocin (TPM1) gene [17, 31]. The JPH2 p.
(Thr161Lys) variant presented here differs from the other two in clinical presentations. The
JPH2 variant associates with earlier disease onset (27 years vs. 52 and 49 years) than the
MYBPC3 p.(Gln1061) or TPM1 p.(Asp175Asn), respectively, although no patients under age
of 16 were included in the previous study [17]. Systolic heart failure was observed in 5 (25%)
and LV dysfunction was present in half of the affected patients with JPH2 variant when defined
by EF<47% or elevated proBNP. Of the probands with MYBPC3 p.(Gln1061), none has had
congestive heart failure. However, dyspnea was present in 31%. Also none of the index patients
with the TPM1 p.(Asp175Asn) mutation had significant systolic dysfunction (EF<46%) and
only one (5%) had a history of systolic heart failure. Severe conduction defects defined by
3-degree AV-block or R/LBBB was observed in nine (45%) and AF in nine (45%) of the
affected individuals or obligate carriers with JPH2 variant, but no SCDs were detected in our
families. Of the individuals with MYBPC3 p.(Gln1061) variant, 26% presented syncope/pre-
syncope, 23% had either chronic or paroxysmal atrial fibrillation, 9% have had sustained VT
or ventricular fibrillation and 26% had family history of SCD. Three out of 34 (9%) HCM
patients carrying the TPM1 p.(Asp175Asn) presented with a documented SCD at young or
middle age [31]. Additionally, life-threatening arrhythmias were induced with programmed
ventricular stimulation (PVS) in one third of patients carrying this mutation. Of the probands
with TPM1 or MYBPC3 founder mutation, ICD was implanted in 2 (10%) and 7 (20%) patients
respectively and no significant conduction problems necessitating pacemaker implantation
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where described in the index publications. These observations highlight the significant differ-
ences in clinical presentation of the patients with the previously characterized founder muta-
tions compared to proposed JPH2 mutation described in this study. However, the degree of
LV hypertrophy may be similar in patients with these founder mutations (22±5 mm, 18±6 mm
and 20±5 mm with variant in MYPBC3, TPM1 or JPH2, respectively), although the JPH2 vari-
ants carriers were younger at a time of evaluation compared to carriers of other founder muta-
tions. It should be still keep in mind that significant variation in clinical presentation within
and between the families with the same mutation exists in all types of HCM.
There are altogether 19 JPH2 variants associating with dilated or hypertrophic cardiomyop-
athy listed in the HGMD (Qiagen) and ClinVar databases (July 8, 2017) presented in Table 2.
Seventeen of them are missense variants. Before this study, no convincing evidence of segrega-
tion within large pedigrees except for the p.(Glu85Lys) [25] and no de novo JPH2 mutations
have been reported in patients with HCM. In 2007, Landstrom et al. found two rare missense
Table 2. All JPH2 variants described in literature and rare JPH2 variants submitted to ClinVar Database with phenotype information.
JPH2 Variant
(NM_020433.4)
Pheno gnomAD PP MT Index
(n)
Family
(n)
Co-seg Class Other Reference
c.253G>A, Glu85Lys DCM 0/0 D D 1 9 Yes LP Penetrance 78% (Sabater-Molina et al. 2016)
c.301A>C, Ser101Arg HCM 0/0 PD B 1 0 No VUS (Landstrom et al. 2007)
c.421T>C, Tyr141His HCM 0/0 D D 1 0 No VUS (Landstrom et al. 2007)
c.494C>T, Ser165Phe HCM 0/0 D D 1 0 No VUS (Landstrom et al. 2007)
c.502A>C, Ser168Arg HCM 0/0 D D 1 0 Np VUS ClinVar 222654
c.505G>A, Glu169Lys HCM 0/0 D D 1 1 ? VUS (Beavers et al. 2013)
c.559G>A, Gly187Ser HCM 1/0 PD B 1 0 No VUS ClinVar 222655
c.565G>A, Ala189Thr SUD 94/0 B B 1 0 No LB (Narula et al. 2015)
c.692G>A, Arg231Gln Sdr 39/0 D B 1 0 No LB (Farwell et al. 2015)
c.723C>G, Ser241Arg DCM 0/0 D D 1 0 No VUS ClinVar 155801
c.1013A>G,
Glu338Gly
SCD 0/0 D D 1 0 No VUS Enlarged RV (Neubauer et al. 2016)
c.1213G>T, Ala405Ser HCM 3/0 D D 1 0 No VUS Ala405Thr 18 het gnomAD, De
novo?
(Beavers et al. 2013)
c.1227C>G,
Asn409Lys
DCM 0/0 PD D 1 0 No VUS ClinVar 222656
c.1282C>T, Gln428 DCM 13/0 - - 1 0 No VUS ClinVar 222657
c.1513G>A,
Gly505Ser
HCM 589/7 B B 4 0 No Benign (Matsushita et al. 2007, Manrai et al.
2016)
c.1540G>A,
Gly514Ser
LVNC 1/0 D D 1 0 No VUS ClinVar 222658
c.1564C>T,
Arg522Trp
DCM 0/0 D D 1 0 No VUS ClinVar 222659
c.1750C>A,
Gln584Lys
LVNC 1/0 B B 1 0 No VUS ClinVar 180592
c.2011-1G>T HCM 0/0 - - 1 0 No VUS (Xu et al. 2015)
Abbreviations: Pheno, phenotype; gnomAD, number of heterozygotes/homozygotes in the gnomad reference population consisting 120,000 individuals; PP, PolyPhen;
MT, MutationTaster; D, probably damaging in PolyPhen and disease causing in MutationTaster; PD, possibly damaging; B, benign in PolyPhen and polymorphism in
MutationTaster; Index, number of index patients, Family, number of affected family members with the same variant as index patient; Co-seg, co-segregation; Class,
classification of the variant by the authors relying on ACMG recommendation; LP, likely pathogenic; VUS, variant of uncertain significance; LB, likely benign; SUD,
Sudden unexplained death; Sdr, complex syndrome
, Non-pass (low quality) variant in gnomAD; LVNC, left ventricular non-compaction cardiomyopathy. Other abbreviations as in Table 1.
https://doi.org/10.1371/journal.pone.0203422.t002
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and one frameshift variant in JPH2 in three probands with HCM but their families were not
studied or genotyped [28]. In 2016, Sabater-Molina showed segregation of the JPH2 p.
(Glu85Lys) with dilated cardiomyopathy with or without left ventricular non-compaction car-
diomyopathy (LVNC) features in a large family [25]. Furthermore, Quick et al have recently
published JPH2 p.(Ala405Ser) variant in a single patient with basal septal hypertrophy and dia-
stolic dysfunction [32]. Most of the previously published variants are absent or rare in ExAC
or gnomAD reference populations and thus they have potential to be disease causing. Truncat-
ing JPH2 variants are relatively rare in ExAC reference population (carrier frequency 1 per
6,030 individuals) but due to small size of the gene, the pLI value is 0.01 which does not suggest
that loss of function alterations would be poorly tolerated. The clinical data on HCM related to
the previously published JPH2 missense variants is limited, mostly clinical HCM appears to be
diagnosed after teenage but at least the patient with p.(Glu169Lys) exhibited HCM already at
the age of 5 months [30], similarly as two patients in this study.
We identified one family (Family 6) where all three affected individuals carry the well-
established pathogenic MYBPC3 variant, p.(Gln1061), in addition to JPH2 p.(Thr161Lys) var-
iant. Their phenotypic presentation did not differ significantly from the other families which
are surprising as patients with homozygosity/compound heterozygosity or digenic pathogenic
variants in sarcomere genes generally present at very early age [33–36]. In literature at least
nine patients have been described who had homozygous or confirmed compound heterozy-
gous disease causing variant in MYBPC3 and at least the other variant is not truncating. In
these patients the mean age at onset was 4.1 years. Three of these cases presented at neonatal
phase, of which all died before age of two months [34, 35]. All patients with homozygous or
compound heterozygous truncating pathogenic mutations in MYBPC3 reported so far
(n = 21) were diagnosed with severe cardiomyopathy and/or died within the first few months
of life [35]. At the moment, it is unclear whether compound mutation present in sarcomere
and non-sarcomere gene simultaneously have additive detrimental effect on disease onset and/
or progression.
In conclusion, the JPH2 p.(Thr161Lys) is classified as pathogenic based on ACMG classifi-
cation scheme [37], as the variant resides in a conserved position, is predicted to be deleterious
by in silico prediction tools, is absent in control populations and co-segregates with dominant
HCM in six families. These observations strengthen the role of non-sarcomeric JPH2 as a caus-
ative gene for HCM with or without systolic heart failure and conduction abnormalities. Fur-
ther research is warranted to evaluate JPH2 variants and other genes related to Ca2+ -handling
in the cardiomyocyte to further shed light on the genetic background of HCM. Variant inter-
pretation and correlation to phenotype is still challenging as earlier studies form major pitfalls
by false classifications related to small reference populations, co-incidental segregations and
evaluation of only a small subset of the potentially meaningful genes behind a patient’s pheno-
type. Large-scale genetic research will eventually bring more consistency to the evaluation of
families with inherited cardiac diseases. Unfortunately, most of the submissions of the JPH2
variants in ClinVar reviewed in this work did not include phenotype data and thus provide
limited information for the clinical society. Variant sharing with relevant information of the
phenotype in mutation databases is critically important to develop the field further on.
Supporting information
S1 Protocol. Genetic panels used for the family probands. Probands of each family were
evaluated by either Blueprint Genetics Core Cardiomyopathy Panel (Family 1, 2, 3, 6, 7) or
Pan Cardiomyopathy Panel (Family 4, 5, 8, 9). These next generation sequencing (NGS) panels
are targeted into all protein coding exons and exon-intron boundaries of all target genes (listed
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tions, deletions and indels up to 46 bp. The panels have ISO 15189 and CAP accreditation.
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